Kamm J Lacy, Riley Christopher B, Parlane Natalie, Gee Erica K, McIlwraith C Wayne
School of Veterinary Science, Massey University, Palmerston North, New Zealand.
Hopkirk Laboratory, AgResearch, Palmerston North, New Zealand.
Front Vet Sci. 2021 Jan 13;7:617647. doi: 10.3389/fvets.2020.617647. eCollection 2020.
Despite significant immunosuppressive activity, allogeneic mesenchymal stromal cells (MSCs) carry an inherent risk of immune rejection when transferred into a recipient. In naïve recipients, this immune response is initially driven by the innate immune system, an immediate reaction to the foreign cells, and later, the adaptive immune system, a delayed response that causes cell death due to recognition of specific alloantigens by host cells and antibodies. This review describes the actions of MSCs to both suppress and activate the different arms of the immune system. We then review the survival and effectiveness of the currently used allogeneic MSC treatments.
尽管同种异体间充质基质细胞（MSCs）具有显著的免疫抑制活性，但当将其移植到受体中时，仍存在免疫排斥的固有风险。在未接触过抗原的受体中，这种免疫反应最初由先天性免疫系统驱动，即对外来细胞的即时反应，随后由适应性免疫系统驱动，这是一种延迟反应，由于宿主细胞和抗体识别特定的同种异体抗原而导致细胞死亡。这篇综述描述了间充质基质细胞对免疫系统不同分支的抑制和激活作用。然后，我们回顾了目前使用的同种异体间充质基质细胞治疗的存活率和有效性。
